Sidoti Downgrades Heska Corp. (HSKA) to Neutral
Heska Corp. (NASDAQ:HSKA) was downgraded by investment analysts at Sidoti from a “buy” rating to a “neutral” rating in a research note issued to investors on Monday. They presently have a $71.00 target price on the stock. Sidoti’s price target indicates a potential upside of 7.06% from the company’s current price.
Several other brokerages have also recently weighed in on HSKA. B. Riley reaffirmed a “neutral” rating and issued a $55.50 target price on shares of Heska Corp. in a report on Monday, November 7th. Zacks Investment Research raised shares of Heska Corp. from a “hold” rating to a “buy” rating and set a $63.00 target price on the stock in a report on Wednesday, November 2nd. Finally, Gabelli cut shares of Heska Corp. from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $63.17.
Shares of Heska Corp. (NASDAQ:HSKA) opened at 66.32 on Monday. The firm has a market capitalization of $457.48 million, a PE ratio of 53.10 and a beta of 0.74. Heska Corp. has a 52 week low of $26.25 and a 52 week high of $69.80. The firm’s 50-day moving average is $57.86 and its 200 day moving average is $48.13.
Heska Corp. (NASDAQ:HSKA) last issued its quarterly earnings results on Tuesday, November 1st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.25 by $0.20. The business had revenue of $33.40 million for the quarter, compared to analysts’ expectations of $31.36 million. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities analysts forecast that Heska Corp. will post $1.32 earnings per share for the current year.
In other Heska Corp. news, CFO Jason A. Napolitano sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $52.53, for a total value of $262,650.00. The sale was disclosed in a document filed with the SEC, which is available through this link. 15.30% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. Rhumbline Advisers raised its position in shares of Heska Corp. by 1.5% in the third quarter. Rhumbline Advisers now owns 6,056 shares of the company’s stock worth $330,000 after buying an additional 90 shares during the period. California State Teachers Retirement System raised its position in shares of Heska Corp. by 0.8% in the third quarter. California State Teachers Retirement System now owns 12,890 shares of the company’s stock worth $702,000 after buying an additional 100 shares during the period. BlackRock Inc. raised its position in shares of Heska Corp. by 6.2% in the third quarter. BlackRock Inc. now owns 5,413 shares of the company’s stock worth $295,000 after buying an additional 318 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Heska Corp. by 7.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 4,853 shares of the company’s stock worth $180,000 after buying an additional 320 shares during the period. Finally, Analytic Investors LLC raised its position in shares of Heska Corp. by 0.9% in the third quarter. Analytic Investors LLC now owns 37,289 shares of the company’s stock worth $2,030,000 after buying an additional 334 shares during the period. Institutional investors and hedge funds own 72.70% of the company’s stock.
Heska Corp. Company Profile
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Stock Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related stocks with our FREE daily email newsletter.